Hims & Hers Health (NYSE:HIMS) Insider Sells $141,435.00 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 4,490 shares of Hims & Hers Health stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $141,435.00. Following the completion of the sale, the insider directly owned 6,790 shares of the company’s stock, valued at $213,885. The trade was a 39.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Irene Becklund also recently made the following trade(s):

• On Tuesday, June 16th, Irene Becklund sold 7,573 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.25, for a total transaction of $229,083.25.

Hims & Hers Health Trading Down 0.1%

Shares of NYSE:HIMS opened at $35.44 on Friday. The company has a market cap of $8.20 billion, a PE ratio of -393.79, a price-to-earnings-growth ratio of 50.70 and a beta of 2.37. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The stock has a 50 day moving average of $26.74 and a 200 day moving average of $26.64. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.20 EPS. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on HIMS shares. Citigroup upped their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Jefferies Financial Group set a $24.50 price objective on shares of Hims & Hers Health in a report on Tuesday, May 12th. TD Cowen cut their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research note on Friday, March 27th. Weiss Ratings downgraded Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Finally, BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $29.37.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in the stock. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health in the third quarter valued at about $28,000. Silicon Valley Capital Partners purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at approximately $48,000. Flagship Harbor Advisors LLC purchased a new stake in Hims & Hers Health in the fourth quarter valued at $28,000. Bogart Wealth LLC raised its holdings in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares during the period. Finally, Smartleaf Asset Management LLC raised its stake in shares of Hims & Hers Health by 44.7% in the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after acquiring an additional 283 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.